Toward Control? The Prospects and Challenges of Typhoid Conjugate Vaccine Introduction.
Communicable Disease Control
/ legislation & jurisprudence
Disease Outbreaks
/ prevention & control
Global Health
Humans
Salmonella typhi
/ immunology
Sanitation
Typhoid Fever
/ prevention & control
Typhoid-Paratyphoid Vaccines
/ administration & dosage
Vaccination
/ legislation & jurisprudence
Vaccines, Conjugate
/ administration & dosage
Water
World Health Organization
public awareness
typhoid conjugate vaccine
typhoid control
vaccine acceptance
water and sanitation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 10 2019
15 10 2019
Historique:
entrez:
16
10
2019
pubmed:
16
10
2019
medline:
15
9
2020
Statut:
ppublish
Résumé
With a newly World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible countries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful communication planning and community engagement to counter vaccine hesitancy.
Identifiants
pubmed: 31612940
pii: 5587096
doi: 10.1093/cid/ciz483
pmc: PMC6792119
doi:
Substances chimiques
Typhoid-Paratyphoid Vaccines
0
Vaccines, Conjugate
0
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S408-S411Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
mBio. 2018 Mar 20;9(2):
pubmed: 29559573
BMJ Open. 2017 Jul 2;7(6):e016283
pubmed: 28674145
Eur J Epidemiol. 1996 Aug;12(4):409-12
pubmed: 8891547
Expert Rev Anti Infect Ther. 2011 Jun;9(6):711-25
pubmed: 21692675
Clin Infect Dis. 2019 Mar 5;68(6):949-955
pubmed: 30020426
Clin Infect Dis. 2019 Oct 15;69(Suppl 5):S377-S384
pubmed: 31612942
Wkly Epidemiol Rec. ;92(48):729-47
pubmed: 29192459
Eur J Epidemiol. 2005;20(7):635-42
pubmed: 16119438
Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S22-S26
pubmed: 30767002
BMJ. 2019 Feb 14;364:l739
pubmed: 30765388
Vaccine. 2017 Sep 12;35(38):5081-5088
pubmed: 28802757
J Infect Dis. 2018 Nov 10;218(suppl_4):S188-S194
pubmed: 30304505
J Infect Dis. 2018 Nov 10;218(suppl_4):S250-S254
pubmed: 30060082
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S42-S45
pubmed: 30766999
EMBO Mol Med. 2019 Oct;11(10):e10431
pubmed: 31468702
Clin Infect Dis. 2019 Oct 15;69(Suppl 5):S388-S394
pubmed: 31612939
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S4-8
pubmed: 26933019
PLoS Negl Trop Dis. 2018 Oct 11;12(10):e0006779
pubmed: 30307935
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Pan Afr Med J. 2018 Mar 13;29:148
pubmed: 30050612